Brought to you by 
NantPharma gets $125mm in early-stage funding from Blackstone
14 Jan 2021
Executive Summary
NantPharma LLC, the pharmaceutical research and manufacturing division of NantWorks LLC (integrating a variety of technologies into new approaches for diagnostic and therapeutic development) has received $125mm from the Blackstone Group in what appears to be the entity’s first financing round. Three partners from Blackstone have joined NantPharma’s board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NantPharma gets $125mm in early-stage funding from Blackstone
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice